Moderna Q4 Earnings Call Highlights

• 3 ETFs Catapulting Beyond the S&P to Start the Year

Moderna (NASDAQ:MRNA) executives highlighted advancement connected outgo reductions, a ramp successful planetary partnerships, and aggregate late-stage pipeline milestones during the company’s fourth-quarter 2025 net call, portion besides addressing disappointment with a U.S. Food and Drug Administration refusal-to-file missive for its seasonal influenza vaccine candidate, mRNA-1010.

Chief Executive Officer Stéphane Bancel said 2025 gross totaled $1.9 billion, driven by income of the company’s COVID-19 vaccines Spikevax and mNEXSPIKE. He besides emphasized outgo progress, noting operating expenses declined by $2.2 billion, oregon 30%, twelvemonth implicit year. Moderna posted a nett nonaccomplishment of $2.8 cardinal for 2025 and ended the twelvemonth with $8.1 cardinal successful currency and investments.

→ Once Upon A Farm: Buy the $1B Growth Story?

• MarketBeat Week successful Review – 01/19 - 01/23

Chief Financial Officer Jamey Mock said fourth-quarter gross was $700 million, with $300 cardinal from the U.S. and $400 cardinal from planetary markets, landing astatine the higher extremity of caller guidance. Full-year U.S. gross was $1.2 billion, with $700 cardinal internationally. Mock said Moderna saw beardown U.S. retail marketplace stock supported by the motorboat of mNEXSPIKE, adjacent arsenic wide COVID request declined twelvemonth implicit year.

For the 4th quarter, Moderna reported a nett nonaccomplishment of $800 million, compared to a nett nonaccomplishment of $1.1 cardinal successful the 4th fourth of 2024. Loss per stock was $2.11 versus $2.91 a twelvemonth earlier. For 2025, nonaccomplishment per stock was $7.26 compared to $9.28 successful 2024.

→ No Rally? Coca-Cola’s Results Still Look Like a Sweet Deal

• Moderna Pops 17%—Is There Life successful MRNA, Down 90% from COVID High?

Mock elaborate full-year disbursal trends, including a 41% alteration successful outgo of income to $868 million, which helium attributed chiefly to productivity and little inventory write-downs, declaration manufacturing, wind-down costs, and income volumes. R&D disbursal declined 31% to $3.1 cardinal owed to concern prioritization and proceedings execution efficiencies, partially offset by accrued concern successful norovirus and oncology programs. SG&A disbursal fell 13% to $1.0 billion.

Bancel said the institution was “disappointed” by the FDA refusal-to-file missive for mRNA-1010 and argued that unpredictability successful expectations and timelines tin dilatory concern and hold diligent access. President Stephen Hoge said Moderna has requested a Type A gathering with the FDA to clarify a way guardant for the flu programme successful the U.S., describing the process arsenic typically astir 30 days.